摘要
目的观察吉西他滨联合顺铂治疗晚期乳腺癌的疗效及不良反应。方法采用吉西他滨联合顺铂治疗晚期（术后复发或转移）乳腺癌96例。吉西他滨1000 mg/m2,静脉滴注,第1,8天;顺铂70 mg/m2,静脉滴注,第2天,21-28 d为一周期。结果总有效率为58.3%,中位病情进展时间7个月,中位生存时间20个月,1年生存率为60.2%,3年生存率23.1%,5年生存率5.8%。初治组有效率显著优于复治组（82.7%对29.5%,P〈0.05）,曾经使用过蒽环类药物和未使用过蒽环类药物患者有效率差异无显著性（51.4%对66.7%,P〉0.05）,曾经用过紫杉类药物和未使用紫杉类药物患者的有效率差异无显著性（50.0%对51.7%,P〉0.05）。有1-2个转移灶组和3个转移灶组有效率差异无显著性（68.9%对48.6%,P〉0.05）,此方案对于内脏、软组织、淋巴结转移灶有效率相近,骨转移灶有效率相对较低（28.6%）。主要不良反应为骨髓抑制、胃肠道反应、肝肾功能异常,多为Ⅰ-Ⅱ度;Ⅲ-Ⅳ度不良反应主要为白细胞减少和胃肠道反应,发生率分别为16.7%和12.5%。结论吉西他滨联合顺铂治疗晚期乳腺癌具有较好的疗效,不良反应可耐受。
Objective To evaluate the efficacy and safety of gemcitabine combined with cisplatin regimen in treating advanced breast cancer.Methods A total of 96 patients with advanced breast cancer were treated with combination of gemcitabine and cisplatin.Gemcitabine was administered at 1000mg/m2 iv d1,8,and cisplatin was administered at 70 mg/m2 iv d2.The above regimen was repeated every 21-28 days.Results The overall response rate was 58.3%,with a median time to progression of 7 months.The median survival time was 20 months. The 1-year,3-year and 5-year survival rates were 60. 2% ,23.1%, and 5.8% respectively. The response rate was significantly higher in patients receiving the initial treament than in those receiving retreatment（82. 7% vs 29.5% , P 〈 0.05 ）. The response rate was 51.4% in patients previously treated with turn anthracyclines and 66. 7% in patients without previous anthracyclines treatment. The response rates were not significantly different between patients previously treated with paelitaxel and those without previous paelitaxel treatment（ 50. 0% vs 51.7%, P 〉 0. 05 ）. The response rates in patients with one or two metastatic lesions and those with more than three lesions were 68.9% and 48.6% respectively （ P 〉 0. 05 ）. Compared with metastases in viscera,lymph nodes and soft tissues,the response rate in patients with bone metastasis was relatively low （ 28. 6% ）, but with no statistical significant difference. The main side effects were myelosuppression, gastrointestinal toxicity and abnormal hepatic function. Most of above side effects were grade Ⅰ-Ⅱ. The main grade Ⅲ-Ⅳ side effects were leukopenia and gastrointestinal toxicity with incidence of 16. 7% and 12.5% ,respectively. Conclusion The combination of gemcitabine and cisplatin has high efficacy in treating patients with advanced breast cancer. The side effects are tolerable.
出处
《中国肿瘤临床与康复》
2009年第5期438-440,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
乳腺肿瘤
吉西他滨
顺铂
Breast neoplasms
Gemcitabine
Cisplatin
